Skip to main content

Table 1 Antibody-drug conjugates in clinical trials for lymphoma

From: Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress

ADC Target Linker Payload Indication Result Trial
ADCs approved for lymphoma
Brentuximab vedotin CD30 Val-Cit MMAE R/R HL ORR 75%, CR 34% phase II [48]
R/R HL ORR 54.4%, median PFS 8.2 months phase III [49]
R/R HL ORR 75%, CR 42% phase I [51]
Post-ASCT consolidation for HL Median PFS 42.9 months, 5-year PFS 59% phase III [52]
Post-ASCT consolidation for HL 18-month PFS 95%, 18-month OS 98% phase II [53]
Salvage therapy for R/R HL 2-year OS 95%, 2-year PFS 74% phase II [54]
Salvage therapy for R/R HL ORR 84%, CR 79% phase II [55]
Salvage therapy for R/R HL ORR 85%, CR 67%, 2-year PFS 78% phase I/II [56]
Untreated HL ORR 86%, CR 73%, 5-year PFS 82% phase III [58]
Untreated HL ORR 61%, CR 48% phase II [59]
R/R ALCL and R/R MF ORR4 56.3%, CR 16%, median PFS 17.2 months phase III [60]
R/R CTCL and R/R PTCL ORR 38%, CR 17% phase II [61]
Untreated PTCL ORR 83%, CR 68%, 5-year PFS 51% phase III [63]
Untreated ALCL 2-year EFS 79%, 2-year OS 97% phase II [64]
R/R PMBCL and R/R mediastinal GZL PMBCL: ORR 73%, CR 37%
Mediastinal GZL: ORR 70%, CR 50%
phase I/II [67]
Untreated PMBCL, DLBCL, and GZL ORR 100%, CR 86%, 2-year PFS 85%, phase I/II [68]
Polatuzumb vedotin CD79b Val-Cit MMAE R/R DLBCL and R/R FL FL: ORR 70%, CR 45%;
DLBCL: ORR 54%, CR 21%
phase II [71]
R/R DLBCL ORR 45%, CR 40%, median OS 12.4 months, phase II [25]
R/R DLBCL ORR 65%, CR 31%, median DOR 5.8 months phase I/II [72]
R/R FL ORR 76%, CR 65% phase I/II [73]
Untreated DLBCL ORR 89%, CR 77% phase I/II [74]
Loncastuximab tesirine CD19 Val-Ala PBD dimer R/R NHL ORR 46%, CR 27%, median DOR 5.4 months phase I [76]
R/R DLBCL ORR 48%, CR 24%, median DOR 10.3 months phase II [78]
ADCs explored in clinical settings
Coltuximab ravtansine CD19 SPDB DM4 R/R DLBCL ORR 44%, CR 15% phase II [79]
R/R DLBCL ORR 31% phase II [81]
SGN-CD19A CD19 MC MMAF R/R B-NHL ORR 33%, CR22%, median DOR 40 weeks phase I [82]
MT-3724 CD20 / SLTA R/R DLBCL ORR 30%, CR 10% phase I [100]
Inotuzumab ozogamicin  CD22 Acid-labile Calicheamicin  R/R NHL FL: ORR 87%, 2-year PFS 68%
DLBCL: ORR 74%, 2-year PFS 42%
phase III [88]
R/R NHL ORR 41%, 18-month OS 35% phase III [89]
R/R NHL ORR 53%, CR 20% phase I [90]
R/R B-NHL ORR 84%, CR 24% phase I [91]
R/R indolent B-NHL ORR 67%, CR 31%, median PFS 12.7 months phase II [92]
Pinatuzumab vedotin CD22 Protease-cleavable MMAE R/R DLBCL and R/R indolent NHL DLBCL: ORR 36%,
Indolent NHL: ORR 50%
phase I [96]
R/R DLBCL and R/R FL DLBCL: ORR 60%, CR 26%;
FL: ORR 62%, CR 5%
phase II [71]
TRPH-222 CD22 Non-cleavable Maytansinoid R/R NHL ORR 27.2%, CR 22.7% phase I [97]
R/R HL ORR 69%, CR 44%, median DOR 7.7 months, median PFS 6.7 months phase I [109]
IMGN529 CD37 SMCC DM1 R/R B-NHL ORR 13% phase I [113]
AGS67E CD37 Val-Cit MMAE R/R NHL ORR 22%, CR 14% phase I [116]
STRO-001 CD74 Non-cleavable Maytansinoid Advanced B cell malignancies ORR 25%, CR 6.3% phase I [125]
Iladatuzumab vedotin CD79b Protease-cleavable MMAE R/R B-NHL ORR 85%; DLBCL: ORR 60%, CR 43% phase I [128]
VLS-101 ROR1 UC-961 MMAE R/R NHL MCL: ORR 47%, CR 20%;
DLBCL: ORR 80%, CR 40%
phase I [131]
  1. ADC, antibody-drug conjugate; ASCT, autologous stem cell transplantation; ALCL, anaplastic large cell lymphoma; CTCL, cutaneous T cell lymphoma; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; R/R, relapsed or refractory; CR, complete  response; DLBCL, diffuse large B cell lymphoma; DOR, duration of response; FL, follicular lymphoma; MCL, mantle cell lymphoma; GZL, gray zone lymphoma; CLL, chronic lymphocytic leukemia; PTCL, peripheral T cell lymphoma; MF, mycosis fungoides; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; EFS, event-free survival; ORR4, ORR lasting at least 4 months